{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:14:55Z","timestamp":1751429695061,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-00900-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:02:00Z","timestamp":1751382120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A disproportionality analysis of cardiac arrhythmia associated with bisphosphonates based on the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Feifei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guishui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jbmr.3657","volume":"34","author":"SH Ralston","year":"2019","unstructured":"Ralston, S. H. et al. Diagnosis and management of Paget\u2019s disease of bone in adults: A clinical guideline. J. Bone Min. Res. 34, 579\u2013604. https:\/\/doi.org\/10.1002\/jbmr.3657 (2019).","journal-title":"J. Bone Min. Res."},{"key":"900_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.mcna.2022.10.013","volume":"107","author":"V Gopinath","year":"2023","unstructured":"Gopinath, V. & Osteoporosis Med. Clin. North. Am. 107, 213\u2013225, doi:https:\/\/doi.org\/10.1016\/j.mcna.2022.10.013 (2023).","journal-title":"Med. Clin. North. Am."},{"key":"900_CR3","doi-asserted-by":"publisher","unstructured":"Tang, C. H. & Osteoporosis From molecular mechanisms to therapies 3.0. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms222312725 (2021).","DOI":"10.3390\/ijms222312725"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S2213-8587(24)00225-0","volume":"12","author":"IR Reid","year":"2024","unstructured":"Reid, I. R. & McClung, M. R. Osteopenia: a key target for fracture prevention. Lancet Diabetes Endocrinol. 12, 856\u2013864. https:\/\/doi.org\/10.1016\/S2213-8587(24)00225-0 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"1039490","DOI":"10.3389\/fendo.2023.1039490","volume":"14","author":"E Almuradova","year":"2023","unstructured":"Almuradova, E. & Cicin, I. Cancer-related hypercalcemia and potential treatments. Front. Endocrinol. (Lausanne). 14, 1039490. https:\/\/doi.org\/10.3389\/fendo.2023.1039490 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"152304","DOI":"10.1016\/j.semarthrit.2023.152304","volume":"64","author":"S Liu","year":"2024","unstructured":"Liu, S. et al. Cardiovascular safety of Zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. Semin Arthritis Rheum. 64, 152304. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152304 (2024).","journal-title":"Semin Arthritis Rheum."},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"116647","DOI":"10.1016\/j.bone.2022.116647","volume":"168","author":"AJ Rodriguez","year":"2023","unstructured":"Rodriguez, A. J., Nerlekar, N. & Ebeling, P. R. Cardiac adverse events in bisphosphonate and teriparatide users: an international pharmacovigilance study. Bone 168, 116647. https:\/\/doi.org\/10.1016\/j.bone.2022.116647 (2023).","journal-title":"Bone"},{"key":"900_CR8","doi-asserted-by":"publisher","unstructured":"Rubin, K. H. et al. Cardiovascular and skeletal safety of Zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. Bone 134 https:\/\/doi.org\/10.1016\/j.bone.2020.115296 (2020).","DOI":"10.1016\/j.bone.2020.115296"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"204209861983813","DOI":"10.1177\/2042098619838138","volume":"10","author":"U Kirchmayer","year":"2019","unstructured":"Kirchmayer, U. et al. Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy. Ther. Adv. Drug Saf. 10, 2042098619838138. https:\/\/doi.org\/10.1177\/2042098619838138 (2019).","journal-title":"Ther. Adv. Drug Saf."},{"key":"900_CR10","doi-asserted-by":"publisher","unstructured":"Rodriguez, A. J. et al. Oral bisphosphonate use reduces cardiovascular events in a cohort of Danish patients referred for bone mineral density. J. Clin. Endocrinol. Metab. 105 https:\/\/doi.org\/10.1210\/clinem\/dgaa481 (2020).","DOI":"10.1210\/clinem\/dgaa481"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2938","volume":"12","author":"SY Kim","year":"2010","unstructured":"Kim, S. Y., Kim, M. J., Cadarette, S. M. & Solomon, D. H. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res. Ther. 12, R30. https:\/\/doi.org\/10.1186\/ar2938 (2010).","journal-title":"Arthritis Res. Ther."},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1471-2474-10-113","volume":"10","author":"A Mak","year":"2009","unstructured":"Mak, A., Cheung, M. W., Ho, R. C., Cheak, A. A. & Lau, C. S. Bisphosphonates and atrial fibrillation: bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet. Disord. 10, 113. https:\/\/doi.org\/10.1186\/1471-2474-10-113 (2009).","journal-title":"BMC Musculoskelet. Disord"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","volume":"113","author":"A Sharma","year":"2014","unstructured":"Sharma, A. et al. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am. J. Cardiol. 113, 1815\u20131821. https:\/\/doi.org\/10.1016\/j.amjcard.2014.03.008 (2014).","journal-title":"Am. J. Cardiol."},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","volume":"10","author":"DH Kim","year":"2015","unstructured":"Kim, D. H. et al. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 10, e0122646. https:\/\/doi.org\/10.1371\/journal.pone.0122646 (2015).","journal-title":"PLoS One"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","volume":"23","author":"E Barrett-Connor","year":"2011","unstructured":"Barrett-Connor, E. et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos. Int. 23, 233\u2013245. https:\/\/doi.org\/10.1007\/s00198-011-1546-9 (2011).","journal-title":"Osteoporos. Int."},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1074248420984082","volume":"26","author":"LN Moreland-Head","year":"2021","unstructured":"Moreland-Head, L. N., Coons, J. C., Seybert, A. L., Gray, M. P. & Kane-Gill, S. L. Use of disproportionality analysis to identify previously unknown drug-Associated causes of cardiac arrhythmias using the food and drug administration adverse event reporting system (FAERS) database. J. Cardiovasc. Pharmacol. Ther. 26, 341\u2013348. https:\/\/doi.org\/10.1177\/1074248420984082 (2021).","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R Bohm","year":"2021","unstructured":"Bohm, R. et al. Pharmacovigilance-based drug repurposing: the search for inverse signals via openvigil identifies putative drugs against viral respiratory infections. Br. J. Clin. Pharmacol. 87, 4421\u20134431. https:\/\/doi.org\/10.1111\/bcp.14868 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai, Y. et al. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system. J. Immunother Cancer. 7, 286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2 (2019).","journal-title":"J. Immunother Cancer"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jbmr.4174","volume":"36","author":"KM D\u2019Silva","year":"2021","unstructured":"D\u2019Silva, K. M., Cromer, S. J., Yu, E. W., Fischer, M. & Kim, S. C. Risk of incident atrial fibrillation with Zoledronic acid versus denosumab: A propensity Score-Matched cohort study. J. Bone Min. Res. 36, 52\u201360. https:\/\/doi.org\/10.1002\/jbmr.4174 (2021).","journal-title":"J. Bone Min. Res."},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black, D. M. et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl. J. Med. 356, 1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312 (2007).","journal-title":"N Engl. J. Med."},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckbert","year":"2008","unstructured":"Heckbert, S. R., Li, G., Cummings, S. R., Smith, N. L. & Psaty, B. M. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med. 168, 826\u2013831. https:\/\/doi.org\/10.1001\/archinte.168.8.826 (2008).","journal-title":"Arch. Intern. Med."},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","volume":"265","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen, B., Eiken, P. & Brixen, K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J. Intern. Med. 265, 581\u2013592. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.02065.x (2009).","journal-title":"J. Intern. Med."},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","volume":"336","author":"HT Sorensen","year":"2008","unstructured":"Sorensen, H. T. et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336, 813\u2013816. https:\/\/doi.org\/10.1136\/bmj.39507.551644.BE (2008).","journal-title":"BMJ"},{"key":"900_CR24","doi-asserted-by":"publisher","unstructured":"Tisdale, J. E. et al. Drug-Induced arrhythmias: A scientific statement from the American heart association. Circulation 142 https:\/\/doi.org\/10.1161\/cir.0000000000000905 (2020).","DOI":"10.1161\/cir.0000000000000905"},{"key":"900_CR25","doi-asserted-by":"publisher","unstructured":"Delli Poggi, C., Fusaro, M., Mereu, M. C., Brandi, M. L. & Cianferotti, L. Cardiovascular safety and effectiveness of bisphosphonates: from intervention trials to Real-Life data. Nutrients 14 https:\/\/doi.org\/10.3390\/nu14122369 (2022).","DOI":"10.3390\/nu14122369"},{"key":"900_CR26","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl. J. Med. 357, 1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941 (2007).","journal-title":"N Engl. J. Med."},{"key":"900_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1530\/EJE-20-0650","volume":"184","author":"L Pijnenburg","year":"2021","unstructured":"Pijnenburg, L. et al. Atrial fibrillation in patients treated with intravenous Zoledronic or Pamidronic acid: a pharmacoepidemiological study. Eur. J. Endocrinol. 184, 437\u2013444. https:\/\/doi.org\/10.1530\/EJE-20-0650 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"900_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"Russell, R. G. Bisphosphonates: the first 40 years. Bone 49, 2\u201319. https:\/\/doi.org\/10.1016\/j.bone.2011.04.022 (2011).","journal-title":"Bone"},{"key":"900_CR29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clinthera.2010.03.014","volume":"32","author":"A John Camm","year":"2010","unstructured":"John Camm, A. Review of the cardiovascular safety of Zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin. Ther. 32, 426\u2013436. https:\/\/doi.org\/10.1016\/j.clinthera.2010.03.014 (2010).","journal-title":"Clin. Ther."},{"key":"900_CR30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1742-1241.2010.02335.x","volume":"64","author":"EM Lewiecki","year":"2010","unstructured":"Lewiecki, E. M. et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int. J. Clin. Pract. 64, 821\u2013826. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02335.x (2010).","journal-title":"Int. J. Clin. Pract."},{"key":"900_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1359\/jbmr.091201","volume":"25","author":"M Pazianas","year":"2010","unstructured":"Pazianas, M., Compston, J. & Huang, C. L. Atrial fibrillation and bisphosphonate therapy. J. Bone Min. Res. 25, 2\u201310. https:\/\/doi.org\/10.1359\/jbmr.091201 (2010).","journal-title":"J. Bone Min. Res."},{"key":"900_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11739-014-1125-0","volume":"10","author":"C Cipriani","year":"2015","unstructured":"Cipriani, C. et al. Acute effect of Zoledronic acid on the risk of cardiac dysrhythmias. Intern. Emerg. Med. 10, 151\u2013156. https:\/\/doi.org\/10.1007\/s11739-014-1125-0 (2015).","journal-title":"Intern. Emerg. Med."},{"key":"900_CR33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14740338.2022.2131770","volume":"21","author":"D Arku","year":"2022","unstructured":"Arku, D., Yousef, C. & Abraham, I. Changing paradigms in detecting rare adverse drug reactions: from disproportionality analysis, old and new, to machine learning. Exp. Opin. Drug Saf. 21, 1235\u20131238. https:\/\/doi.org\/10.1080\/14740338.2022.2131770 (2022).","journal-title":"Exp. Opin. Drug Saf."},{"key":"900_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-024-01430-8","volume":"47","author":"V Battini","year":"2024","unstructured":"Battini, V. et al. Timing matters: A machine learning method for the prioritization of Drug\u2013Drug interactions through signal detection in the FDA adverse event reporting system and their relationship with time of Co-exposure. Drug Saf. 47, 895\u2013907. https:\/\/doi.org\/10.1007\/s40264-024-01430-8 (2024).","journal-title":"Drug Saf."},{"key":"900_CR35","doi-asserted-by":"publisher","unstructured":"Farnoush, A., Sedighi-Maman, Z., Rasoolian, B., Heath, J. J. & Fallah, B. Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data. Sci. Rep. 14 https:\/\/doi.org\/10.1038\/s41598-024-74505-2 (2024).","DOI":"10.1038\/s41598-024-74505-2"},{"key":"900_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40290-022-00434-y","volume":"36","author":"BM Knisely","year":"2022","unstructured":"Knisely, B. M., Hatim, Q. & Vaughn-Cooke, M. Utilizing deep learning for detecting adverse drug events in structured and unstructured regulatory drug data sets. Pharm. Med. 36, 307\u2013317. https:\/\/doi.org\/10.1007\/s40290-022-00434-y (2022).","journal-title":"Pharm. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00900-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00900-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00900-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:02:00Z","timestamp":1751382120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-00900-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-00900-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Institutional review board approval was waived for this study because FAERS is a public anonymized database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Reviewer disclosures"}}],"article-number":"20753"}}